Keros Therapeutics KGV 2024

Šta radi Keros Therapeutics?

Keros Therapeutics Inc is a biopharmaceutical company that was founded in 2015 by five biotechnology industry experts. The company is based in Lexington, Massachusetts. Keros is an emerging company that focuses on developing innovative therapies for severe diseases resulting from genetic defects. The business model of Keros Therapeutics Inc is to expand its pipeline of innovative therapies through the research, development, and commercialization of drugs that have highly specific mechanisms of action. Keros' business model aims to develop new and differentiated therapies that focus on modulating biological signals and pathways to improve the treatment of serious diseases. Keros Therapeutics Inc has several divisions that focus on different areas of biotechnology. One division of Keros specializes in the development of RNA-modulating therapies for diseases with genetic defects. These therapies target the modulation of RNA splicing processes to influence the causal factor of severe diseases. Another division of Keros focuses on the development of drugs that target the Wnt signaling pathway, a complex protein signaling network that plays an important role in many processes in the body. These Wnt-related drugs target various disease areas such as cancer and fibrosis to improve the treatment of these conditions. The company is currently in the clinical phase and has brought several products to market in various stages of research. One of Keros' key drug candidates is KER-012, a medication for the treatment of Alpha-1 antitrypsin deficiency, a rare and severe disease that often leads to lung and liver conditions. KER-012 aims to develop more effective treatment options for patients by specifically influencing an RNA splicing mechanism in the cells that is associated with the disease. Another drug candidate from Keros is KER-047, a medication for the treatment of Neurofibromatosis type 1, a rare condition that causes tumors in the nervous system. It targets the Wnt signaling pathway to restore control over tumor proliferation and enlargement. Keros has also established partnerships with other biotechnology companies and academic institutions to expand its research and development capabilities and diversify its pipeline. One notable agreement is the collaboration with Arbutus Biopharma to develop RNA modulators for cardiovascular diseases. Overall, Keros Therapeutics Inc aims to develop innovative and effective therapies for a variety of diseases by focusing on biology and signaling pathways that are responsible for disease progression. With a solid therapy pipeline and an experienced group of biotechnology experts, Keros could soon become a leading company in the biopharmaceutical industry. Keros Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.